secwatch.observer — SEC 8-K summary
======================================

Issuer:     Turn Therapeutics Inc. (TTRX)
CIK:        0002023016
Form:       8-K
Filed at:   2025-10-28T23:59:59+00:00
Accession:  0001104659-25-103160
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Turn Therapeutics enters global supply and development pact with Medline for PermaFusion platform
--------------------------------------------------------------------------------

- Turn grants Medline exclusive worldwide license to use Turn's 510(k) clearance for wound-care field-of-use.
- Medline to lead global commercialization across 100+ countries; Turn provides formulation expertise, IP, and clinical development.
- Initial term of three years with automatic one-year renewals; exclusivity subject to undisclosed volume thresholds.
- Parties to collaborate on line extensions (foams, films, hydrogels, ointments, dressings) incorporating PermaFusion technology.
- Public announcement required within 72 hours of October 23, 2025 effective date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2023016/000110465925103160/0001104659-25-103160-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2023016/000110465925103160/tm2529649d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-103160

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer